X4 Pharmaceuticals (XFOR) Competitors

Xilio Therapeutics (NASDAQ:XLO) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Does the media favor XLO or XFOR?

In the previous week, X4 Pharmaceuticals had 7 more articles in the media than Xilio Therapeutics. MarketBeat recorded 15 mentions for X4 Pharmaceuticals and 8 mentions for Xilio Therapeutics. X4 Pharmaceuticals' average media sentiment score of 0.39 beat Xilio Therapeutics' score of 0.19 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
X4 Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher earnings & valuation, XLO or XFOR?

X4 Pharmaceuticals has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$6.34M	5.79	-$58.24M	-$0.84	-0.84
X4 Pharmaceuticals	$2.56M	6.45	-$37.45M	-$14.84	-0.19

Do analysts prefer XLO or XFOR?

Xilio Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 323.13%. X4 Pharmaceuticals has a consensus target price of $71.17, indicating a potential upside of 2,397.08%. Given X4 Pharmaceuticals' higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
X4 Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, XLO or XFOR?

Xilio Therapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Is XLO or XFOR more profitable?

X4 Pharmaceuticals has a net margin of -311.15% compared to Xilio Therapeutics' net margin of -374.79%. Xilio Therapeutics' return on equity of -342.32% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-374.79%	-342.32%	-67.61%
X4 Pharmaceuticals	-311.15%	-375.31%	-72.87%

Do institutionals & insiders believe in XLO or XFOR?

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by insiders. Comparatively, 2.4% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

X4 Pharmaceuticals beats Xilio Therapeutics on 10 of the 17 factors compared between the two stocks.